Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial

作者：Thomas Powles, Toni K. Choueiri, Laurence Albigès, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, M. Gross-Goupil, Alexandr Poprach, Maria De Santis, Mimma Rizzo, Reshma Shinde, Todd L. Saretsky, He Li, Rodolfo F. Perini, Donna Vickery, Brian I. Rini · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00032-4 · 被引用次数：11 · 研究领域：Renal cell carcinoma treatment、Cancer, Hypoxia, and Metabolism、Cardiac tumors and thrombi